Inhibitors of sodium glucose co-transporter 2 (SGLT2) have long been used in the treatment of diabetes and cardiovascular disease, owing to their modulation of glucose levels. Katsuumi and colleagues now show that, in addition to their glycemic effects, SGLT2 inhibitors modulate senescence immune surveillance by downregulating PD-L1 expression on senescent cells.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baker, D. J. et al. Nature 530, 184–189 (2016).
Katsuumi, G. Nat. Aging https://doi.org/10.1038/s43587-024-00642-y (2024).
Sharpless, N. E. & Sherr, C. J. Nat. Rev. Cancer 15, 397–408 (2015).
Kang, T. W. et al. Nature 479, 547–551 (2011).
Ruscetti, M. et al. Science 362, 1416–1422 (2018).
Ovadya, Y. et al. Nat. Commun. 9, 5435 (2018).
Wang, T. W. et al. Nature 611, 358–364 (2022).
Childs, B. G. et al. Science 354, 472–477 (2016).
Aguayo-Mazzucato, C. et al. Cell Metab. 30, 129–142.e4 (2019).
Claggett, B. et al. Circulation 138, 1599–1601 (2018).
Sugizaki, T. et al. NPJ Aging Mech. Dis. 3, 12 (2017).
Kim, J., Yang, G., Kim, Y., Kim, J. & Ha, J. Exp. Mol. Med. 48, e224 (2016).
Cha, J. H. et al. Mol. Cell 71, 606–620.e7 (2018).
Jenkins, B. J. et al. Cell Metab. 35, 1132–1146.e9 (2023).
Blagih, J. et al. Immunity 42, 41–54 (2015).
Acknowledgements
Research in the author’s laboratory is supported by grants from the National Institute of Aging (1R01AG082800), the Office of the Director from the National Institute of Health (1DP5OD033055), the CSHL Cancer Center support grant (P30CA045508), the Longevity Impetus grant from Norn group, the Manhasset women’s coalition against breast cancer and Swim across America.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.A. is listed as the inventor of several patent applications (62/800,188; 63/174,277; 63/209,941; 63/209,940; 63/209,915; 63/209,924; 17/426,728; 3,128,368; 20748891.7; 2020216486; 63/510,997) related to senolytic chimeric antigen receptor T cells. C.A. is an advisor for Fate Therapeutics.
Rights and permissions
About this article
Cite this article
Guo, G., Amor, C. SGLT2 regulates immune-mediated senolysis. Nat Aging 4, 909–910 (2024). https://doi.org/10.1038/s43587-024-00651-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-024-00651-x
